ஆட்டோ இம்யூன் நரம்பியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆட்டோ இம்யூன் நரம்பியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆட்டோ இம்யூன் நரம்பியல் Today - Breaking & Trending Today

Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting


Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting
Full results from the Vivacity-MG study to be presented for the first time during an oral presentation
News provided by
Share this article
Share this article
TITUSVILLE, N.J., April 16, 2021 /PRNewswire/  The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the full results from the Phase 2 Vivacity-MG study of the investigational compound, nipocalimab (M281), in generalized myasthenia gravis (gMG)–a chronic, autoimmune neuromuscular disease. The data will be featured as part of an oral presentation at the American Academy of Neurology (AAN) Virtual Meeting taking place April 17-22, 2021. ....

United States , Jennifer Mcintyre , Bill Martin , Chris Delorefice , Luc Truyen , None Of The Janssen Pharmaceutical Companies , Energy Study , Momenta Pharmaceuticals Inc , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , Us Food Drug Administration , Companies Of Johnson , American Academy Of Neurology , Lancet Regional Health , American Academy , Virtual Meeting , Autoimmune Neurology , Clinical Trials , Neurologic Disorders , Myasthenia Gravis Activities , Daily Living , Global Head , External Affairs , Janssen Research ,

New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio


Press release content from Business Wire. The AP news staff was not involved in its creation.
New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio
April 8, 2021 GMT
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Apr 8, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Genentech neuroscience portfolio across six therapeutic areas, including Evrysdi™ (risdiplam) for spinal muscular atrophy (SMA), Ocrevus ® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton’s tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III trials for RMS and PPMS, E ....

United States , South San Francisco , Levi Garraway , Karl Mahler , Lisa Tuomi , Movement Disorders , Toddler Development , European Commission , Drug Administration , Global Product Development , Guthy Jackson Charitable Foundation , Risdiplam Clinical Trial Development Program , American Academy Of Neurology , Roche Group , Ms Health Care System Policy Based Research , Clinical Development For Multiple Sclerosis , American Academy , Annual Meeting , Global Product , Muscular Atrophy , Optica Spectrum Disorder , Session Title , Neuromuscular Disorders , Non Ambulant Type , Pharmacodynamic Data , Spinal Muscular Atrophy ,